PALSONIFY turns Crinetics into a real launch story
- Crinetics is now a commercial biotech after PALSONIFY won FDA approval in September 2025 and launched in the U.S. in October 2025.
- Q1 2026 net product revenue reached $10.3 million, up from $5.4 million in the first launch quarter.
- The early launch looks healthier because 15% of Q1 prescriptions came from treatment-naive patients and 15% came from patients returning to care.
- Europe is now open after the European Commission approved PALSONIFY in April 2026, while Japan and Brazil are moving through filings.
- The bear case is cash burn, payer conversion, and competition from injectable drugs, including generic lanreotide.
A launch that may grow the market
Crinetics has crossed the hard line from drug developer to drug seller. PALSONIFY is an oral treatment for adults with acromegaly, a rare disease where the body makes too much growth hormone. It was approved by the FDA in September 2025, launched in the U.S. in October 2025, and was approved in Europe in April 2026.
The early U.S. data matters because PALSONIFY is not only switching patients from older injectable drugs. In Q1 2026, management said 15% of prescriptions came from treatment-naive patients and another 15% came from patients who had stopped prior therapy and came back to care. That hints the pill form may expand the treated market, not only split the old one.
The company also reported $10.3 million of Q1 2026 net product revenue, after $5.4 million in the first launch quarter. It received 232 enrollment forms in Q1, and 263 unique health care providers had prescribed PALSONIFY within the first two quarters of launch. About 70% of patients on therapy were reimbursed by quarter end, which is a good start, but leaves a clear open question.
The bear case has not gone away. Crinetics lost $127.8 million in Q1 2026 and had an accumulated deficit of about $1.5 billion at March 31, 2026. The company is funding a U.S. launch, an international buildout, and several clinical trials at the same time. If payer conversion slows, Europe ramps slowly, or cheaper generic lanreotide blocks use, the launch story could disappoint.
One drug funds a wider endocrine bet
Crinetics runs one integrated business focused on endocrine diseases and endocrine-related tumors. The main money source is now PALSONIFY product sales for acromegaly. In Q1 2026, product revenue was $10.3 million out of $10.7 million total revenue.
A smaller revenue stream comes from collaboration and license revenue, including the Japan partnership with Sanwa Kagaku Kenkyusho, also called SKK. That line was $428 thousand in Q1 2026. For now, it is useful but not the core driver.
The moat is science plus patents. Crinetics focuses on oral, small molecule drugs that target hormone receptors. That matters because many older endocrine treatments are injections. A daily pill can be easier for patients, if doctors trust it and payers cover it.
The model breaks if PALSONIFY does not scale fast enough to carry the cost base. Q1 2026 research and development expense was $100.1 million, and selling, general and administrative expense was $50.8 million. The company raised about $380 million in January 2026, which helps, but it still needs sales growth or more capital over time.
PALSONIFY first, pipeline close behind
PALSONIFY for acromegaly
PALSONIFY, or paltusotine, is the first once-daily oral treatment approved by the FDA and EMA for adults with acromegaly who had an inadequate response to surgery or cannot have surgery. It is the key commercial launch and the main source of product revenue.
Paltusotine for carcinoid syndrome
The CAREFNDR Phase 3 trial is testing paltusotine in carcinoid syndrome linked to neuroendocrine tumors. Success would let Crinetics reuse the same drug platform in a second market.
Atumelnant for CAH
Atumelnant is an oral ACTH receptor antagonist being studied for congenital adrenal hyperplasia, or CAH. The Phase 3 CALM-CAH study and pediatric Phase 2/3 BALANCE-CAH study are ongoing.
Atumelnant for Cushing's disease
Crinetics plans the Phase 2/3 EQUILIBRIUM study in ACTH-dependent Cushing's syndrome. First patient randomization was expected in Q2 2026.
CRN09682 drug conjugate
CRN09682 is a nonpeptide drug conjugate aimed at SST2-expressing neuroendocrine tumors and other solid tumors. It is earlier stage and still needs clinical proof.
Discovery endocrine programs
Crinetics is working on targets such as PTH, SST3, TSHR, growth hormone, GLP-1, and GIP. A new Ohio University collaboration adds work on an oral nonpeptide growth hormone antagonist.
Revenue is still concentrated
Crinetics manages the company as one operating segment. For the three months ended March 31, 2026, the page shows revenue by reported revenue line: product revenue and collaboration and license revenue.
What could break the thesis
Launch stalls after early demand
High impact · Medium oddsPALSONIFY is new, and Crinetics has a short record as a commercial company. Early enrollment forms and prescriber breadth are positive, but repeat use and paid scripts matter more than first starts. If doctors try the drug but do not keep patients on it, revenue can flatten fast.
Payers slow the paid conversion
High impact · Medium oddsManagement said about 70% of patients on therapy were reimbursed by quarter end. That means the remaining patients still need payer approval or another path to paid use. Prior authorization and step therapy could limit how fast new prescriptions become revenue.
Generic lanreotide pressures pricing and access
High impact · Medium oddsPALSONIFY competes against established injectable somatostatin analogs. A generic lanreotide injection was approved in May 2024, which could make payers push patients toward lower-cost injections first. Crinetics must prove the pill is worth access and price support.
Cash burn stays heavy
High impact · Medium oddsCrinetics lost $127.8 million in Q1 2026 while spending on the launch and multiple trials. The January 2026 financing added about $380 million, but losses can still add up. If sales do not scale, shareholders may face more dilution later.
Pipeline trials miss or fall behind
Medium impact · Medium oddsMuch of the long-term value still depends on paltusotine in carcinoid syndrome and atumelnant in CAH and Cushing's disease. These trials can fail, run late, or show weaker safety or efficacy than hoped. Neurocrine's approved crinecerfont also raises the bar in classic CAH.
Europe opens slowly
Medium impact · Medium oddsThe European Commission approved PALSONIFY in April 2026, but approval does not mean instant sales. Country-by-country pricing, reimbursement, and launch timing can take time. Management has also talked about pacing international investment, which may slow near-term ex-U.S. revenue.
In one breath
What does Crinetics Pharmaceuticals do?
Crinetics develops and sells oral medicines for rare endocrine diseases, which are diseases tied to hormones. Its first commercial product is PALSONIFY for acromegaly.
Why is PALSONIFY important?
PALSONIFY is the company's first approved product and its main revenue driver. It is also an oral option in a market that has long used injections, which could help some patients start or restart therapy.
Is Crinetics profitable?
No. Crinetics reported a $127.8 million net loss in Q1 2026 and had an accumulated deficit of about $1.5 billion at March 31, 2026. The investment case depends on PALSONIFY growing fast enough while the pipeline advances.
What are the next big events for CRNX?
Investors should watch quarterly PALSONIFY sales, payer reimbursement progress, early Europe launch signs, the EQUILIBRIUM trial start in Cushing's disease, and CAH extension data later in 2026.